(Total Views: 536)
Posted On: 01/11/2020 5:54:23 PM
Post# of 153897
Re: tconway1118 #14805
That study was done with vicriviroc which shuts down all chemokine interactions and all immune response. Which accounts for it's bad side effects and it being stopped from doing anymore trials. It's like maraviroc but worse.
On the other hand leronlimab allows a limited immune response (the difference between small and large molecule CCR5 mabs).
Entry into the cells makes no difference, it's the immune response aided by CCR5 that would need to be curbed.
With 1/3rd of flu deaths being caused by an over-active immune response and inflammation limiting that immune response would certainly save lives. The one thing to be determined would be the appropriate dosage of leronlimab. Most likely a 350mg dose or less would be appropriate to balance immune response.
On the other hand leronlimab allows a limited immune response (the difference between small and large molecule CCR5 mabs).
Entry into the cells makes no difference, it's the immune response aided by CCR5 that would need to be curbed.
With 1/3rd of flu deaths being caused by an over-active immune response and inflammation limiting that immune response would certainly save lives. The one thing to be determined would be the appropriate dosage of leronlimab. Most likely a 350mg dose or less would be appropriate to balance immune response.
(2)
(0)
